A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adult Patients With Major Depressive Disorder.

Trial Profile

A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adult Patients With Major Depressive Disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2016

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 20 May 2015 Pooled long term tolerability analysis, results presented at the 168th Annual Meeting of the American Psychiatric Association.
    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 May 2012 Actual initiation date changed from 1 Feb 2011 to 1 Sep 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top